secwatch.observer — SEC 8-K summary
======================================

Issuer:     Intellia Therapeutics, Inc. (NTLA)
CIK:        0001652130
Form:       8-K
Filed at:   2024-06-14T23:59:59+00:00
Accession:  0000950170-24-073709
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Intellia appoints Brian Goff to board; former Alexion commercial executive
--------------------------------------------------------------------------

- Appointed as Class I director effective June 13, 2024; term through 2026 annual meeting.
- Goff is CEO of Agios Pharmaceuticals; over 30 years biopharma commercial experience including EVP at Alexion.
- Received option for 22,297 shares at $25.96 and 15,409 RSUs, vesting over three years.
- Appointed to Compensation and Talent Development Committee; independent under Nasdaq rules.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1652130/000095017024073709/0000950170-24-073709-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1652130/000095017024073709/ntla-20240612.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-073709

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer